4-(4,4,5,5-Tetramethyl-1,3,2-dioxaborolan-2-yl)furan-2-carbaldehyde, 95.0%, 1g

[3-(4-Methoxyphenyl)isoxazol-5-yl]methanol, 95.0%, 10g

N-Ethylcyclopropanamine hydrochloride, 96%, 250mg

2-Bromo-4,5-difluorobenzoic acid, 97.0%, 25g

Oxion Inverso OX.2053-PLPH-ICSI avec objectifs LWD Plan phase 10x/20x/40x, équipement ICSI et table croisée XY

6-Chloro-4-methylpyridine-2-carboxylic acid, 95.0%, 5g

4-Bromo-2-methoxy-3-methylaniline, 5g

Methyl 2-((4-bromophenyl)(tert-butoxycarbonyl)amino)acetate, 95.0%, 250mg

Ethyl 2-amino-1-[trans-4-[(tert-butyldimethylsilyl)oxy]cyclohexyl]-1H-benzo[d]imidazole-5-carboxylate, 98%, 50mg

Colonne capillaire GC ROTI®Cap-1701, 15 m, 0,53 mm, 1,00 µm, 1 pièce(s)

2-(Methylthio)quinoline, 97%, 1g

3-BROMO-5-CHLOROQUINOLINE, 95.0%, 250mg

6-Formylpicolinonitrile, 95.0%, 5g